Skip to Content

Molecular Pharmacology USA Ltd MLPH Stock Quote

| Rating as of


Last close prices updated as of Feb 01, 2023, 3:46 PM EST | USD
  • Last Close 0.0001
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  < 0.01
  • Market Cap 11,155.3740
  • Volume / Avg 1,980.0 /  1,199.6
  • Price / Sales 0.00
  • Price / Book
  • Forward Div Yield 2.51%
  • Trailing Div Yield

Morningstar‘s Stock Analysis MLPH

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MLPH

Company Profile MLPH

Business Description

Molecular Pharmacology USA Ltd is a development-stage biotechnology company, through its subsidiary is engaged in the business of developing and commercializing a new analgesic and anti-inflammatory molecule known as Tripeptofen. Tripeptofen is likely to appear in a new group of products suitable for the treatment of common everyday pain. As an analgesic and anti-inflammatory drug, Tripeptofen is unusual due to its rapid speed of action and its topical or rub-on application. The majority of over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs. Geographically, the business presence of the firm is seen across the region of Australia and the USA.

284 Oxford Street, Drug Discovery Research Centre
Perth, WA, 6007, AUS
Industry Biotechnology

FAQs for Molecular Pharmacology USA Ltd Stock

Yes. MLPH has a forward dividend yield of 2.51%. See MLPH’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

MLPH’s market cap is 11,155.37.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

MLPH’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare MLPH’s historical performance against its industry peers and the overall market.